biospaceApril 18, 2018
Tag: Hemophilia , Bioverativ
Bioverativ Inc., a Sanofi company dedicated to transforming the lives of people with rare blood disorders, joins the global hemophilia community in recognizing World Hemophilia Day 2018. To honor this year’s theme, Sharing Knowledge Makes Us Stronger, Bioverativ is sharing the stories of people with hemophilia in the developing world and highlighting the life-changing impact treatment can make.
In 2014, Bioverativ and Swedish Orphan Biovitrum AB (publ) (Sobi) pledged to donate up to one billion international units (IUs) of clotting factor over 10 years, including up to 500 million IUs to the WFH Humanitarian Aid Program over a period up to five years, to help transform the way hemophilia care is delivered in the developing world. Since donations began in 2015, more than 15,000 people with hemophilia in 40 countries have already been treated with over 260 million IUs of medicine donated by Bioverativ and Sobi to the WFH Humanitarian Aid Program. The far-reaching impact of this donation includes:
"I have witnessed the profound impact that donated factor has on those living with hemophilia in developing countries, and we thank Bioverativ and Sobi for their visionary leadership," said Alain Weill, WFH President. "Whether for acute bleeds or prophylactic treatment, or to enable necessary surgeries, these donations are life-changing for patients and their families."
"We believe that all people with hemophilia should have predictable and sustainable access to the treatment they need, regardless of where they live," said John Cox, CEO at Bioverativ. "Bioverativ is proud to support the efforts of the World Federation of Hemophilia to raise the standard of care and improve outcomes for those most in need in developing countries."
As part of World Hemophilia Day, Bioverativ will also join with the WFH and the broader hemophilia community to raise awareness and encourage ongoing support for those living with bleeding disorders by:
About Bioverativ, a Sanofi company
Bioverativ, a Sanofi company, is dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development, and commercialization of innovative therapies. Bioverativ is committed to actively working with the blood disorders community, and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: